Cellebrite DI Ltd. Form 6-K Summary
Business Context and Reporting Period
This Form 6-K was filed by Cellebrite DI Ltd. on September 2, 2026, for the month of September 2026. The filing serves as a clarification regarding dilution figures previously disclosed in the proxy statement for the 2026 Annual General Meeting of Shareholders.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margins, debt, or liquidity metrics. It focuses exclusively on equity capitalization and share counts as of August 1, 2026.
- Ordinary Shares Outstanding: 251,341,060
- Shares Subject to Outstanding Awards (SIP): 12,917,566
- Shares Available for Future Grant (SIP): 10,418,086
- Shares Available (ESPP): 2,218,509
- Total Shares Reserved for Equity Plans: 25,554,161
- Fully Diluted Share Count: 276,895,221
- Potential Dilution: Approximately 9.2%
Material Changes
The Board of Directors approved a reduction of 3,500,000 ordinary shares reserved for future issuance under the 2021 Share Incentive Plan (SIP) on July 29, 2026. This adjustment was made as part of an ongoing review of the Company's equity compensation program.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, management commentary on operations, or discussion of risks and contingencies beyond the clarification of share counts. The document is incorporated by reference into specific Form S-8 and Form F-3 registration statements.
Investor Verification Checklist
- Verify the impact of the 3,500,000 share reduction on future equity compensation availability.
- Confirm the 9.2% potential dilution figure against the fully diluted share count of 276,895,221.
- Review the referenced proxy statement for the 2026 Annual General Meeting for context on the initial dilution inquiry.
- Check the status of the referenced registration statements (Form S-8 and Form F-3) for any superseding disclosures.